Bimekizumab versus Adalimumab in Plaque Psoriasis
New England Journal of Medicine, 2021 · paper · Clinical trials
A randomized trial in 478 patients with moderate-to-severe plaque psoriasis comparing bimekizumab with adalimumab. At week 16, 86.2% on bimekizumab and 47.2% on adalimumab had a 90% reduction in PASI score. Bimekizumab caused more oral candidiasis and diarrhea.
1 finding
Reference or label Reference 11 reads "Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med 2021; 384:142-52."; the volume appears to be 385.
- p. 12 References, ref. 11
Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med 2021; 384:142-52.
- p. 1 Citation line
N Engl J Med 2021;385:130-41.
Only the authors can say what is right here.
Judge's note: Rests on outside knowledge: the BE RADIANT paper was printed in N Engl J Med 2021;385:142-52, in the same issue as this article. Page 12 image confirms '384:142-52.' The page 1 crop shows this article as 'N Engl J Med 2021;385:130-41', so a page range of 142-52 runs straight on from it, which supports volume 385.
Second check: another model agreed
Report a problem with this finding
3 minor (typos and the like; most checked by the judge only)
Wording Table 3 footnote **: "From weeks 24 to 56, one case each of colon cancer and squamous-cell carcinoma was reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks" gives no site for the SCC, yet NMSC is 0 for that column.
- p. 9 Table 3, footnote ** and NMSC row (weeks 24-56, Q4W→Q8W column)
one case each of colon cancer and squamous-cell carcinoma was reported in the group receiving bimekizumab every 4 weeks and then every 8 weeks
Only the authors can say what is right here.
Judge's note: Page 9 image checked. For weeks 0-24 in the Q4W→Q8W column, NMSC = 3, which matches the 3 basal-cell carcinomas; the anal SCC, which has its site named, is left out. For weeks 24-56 in the same column, Cancer = 2 (1.3) and NMSC = 0, so the unqualified SCC must be non-cutaneous, but the footnote does not say so, unlike the other non-skin SCCs. This is an ambiguity that only the authors can resolve.
Second check: another model agreed
Report a problem with this finding
Typo Table 1 footnote ¶ reads "Dermatology Life Quality Assessment (DLQI)", whereas the Methods define it as "Dermatology Life Quality Index (DLQI)".
- p. 5 Table 1, footnote ¶
Scores on the Dermatology Life Quality Assessment (DLQI) range from 0 to 30
- p. 3 Efficacy End Points
Dermatology Life Quality Index (DLQI)
- p. 5 Table 1 footnote ¶
Dermatology Life Quality Assessment (DLQI)
Judge's note: Page 5 image confirms 'Assessment' in the footnote. The page 3 crop confirms 'Dermatology Life Quality Index (DLQI)' in the Methods. The two expansions of the abbreviation do not match.
Second check: none (judge only)
Report a problem with this finding
Typo Table 1 footnote ‡ reads "Scores on the Psoriasis and Severity Index (PASI)"; 'Area' is missing (should be 'Psoriasis Area and Severity Index').
- p. 5 Table 1, footnote ‡
Scores on the Psoriasis and Severity Index (PASI) range from 0 to 72
- p. 5 Table 1 footnote ‡
Scores on the Psoriasis and Severity Index (PASI)
Judge's note: Page 5 image checked: the footnote prints 'Psoriasis and Severity Index'. The abstract (page 1) and the Methods (page 2) both expand PASI as 'Psoriasis Area and Severity Index'.
Second check: none (judge only)